Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Date:2018-08-24Source: AmoyDx

Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685) announced that NMPA(National Medical Products Administration) approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018. The assay is for qualitative detection of 96 hotspot mutations/fusions in EGFR, KRAS, BRAF, NRAS, HER2, PIK3CA, ALK, ROS1 and RET genes, intended to be used to help clinicians identify multi-targets status for NSCLC patients.

For more information, please call us at +86-592-6806835 or email us at

* Required information
Manage your account info
Change your password